ClinicalTrials.gg
RecruitingNCT06146725RESBIOPUpdated Nov 27, 2023

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

An observational study in Glioblastoma, Glioblastoma, IDH-wildtype and Glioblastoma Multiforme, sponsored by Jasper Gerritsen. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Jasper Gerritsen · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
564
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
13th of 79
564 · median 60
Started
2023
with 57 others
Observational
79 of 1,303
20 open now
Primary completion
2028-01
later than 210 of 322 live
Registered
1,171st of 1,303
by date

Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 13th largest by planned enrollment of the 79 observational ones that give a count, is one of 58 that started in 2023, is one of 79 observational ones, reaches primary completion later than 210 of the 322 other live ones, and was the 1,171st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,303 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment.

This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

Read the detailed description

Trial design This is an international, multicenter, prospective, observational, 2-arm cohort study (registration: clinicaltrials.gov ID number TBA). Eligible patients are treated with either resection or biopsy with a 3:1 ratio with a sequential computer-generated random number as subject ID.

Study objectives The primary study objective is to evaluate safety and efficacy of resection versus biopsy in HGG patients as measured by overall survival (OS) and receipt of adjuvant treatment with chemotherapy and radiotherapy. Secondary study objectives are to evaluate postoperative neurological morbidity, progression-free survival (PFS), postoperative quality of life and SAEs after resection or biopsy as measured by NIHSS deteriration, tumor progression on MRI scans, quality of life questionnaires (QLQ C30, EORTC QLQ BN20, EQ 5D), and recording SAEs respectively.

Study setting and participants Patients will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.

Study patients are allocated to either the supramaximal or maximum safe resection group and will undergo evaluation at presentation (baseline) and during the follow-up period at 6 weeks, 3 months, 6 months and 12 months postoperatively. Motor function will be evaluated using the NIHSS (National Institute of Health Stroke Scale) scale. Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). Patient functioning with be assessed with the Karnofsky Performance Scale (KPS) and the ASA (American Society of Anesthesiologists) physical status classification system. Health-related quality of life (HRQoL) will be assessed with the EORTC QLQ C30, EORTC QLQ BN20 and EQ 5D questionnaires. Overall survival and progression-free survival will be assessed at 12 months postoperatively. We expect to complete patient inclusion in 4 years. The estimated duration of the study (including follow-up) will be 5 years.

03

Conditions studied

  • Glioblastoma
  • Glioblastoma, IDH-wildtype
  • Glioblastoma Multiforme
  • Glioblastoma Multiforme, Adult
  • Glioblastoma Multiforme of Brain

Browse trials for

Keywords

  • Resection
  • Biopsy
  • Survival
  • Quality of life
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with primary high-grade glioma will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤90 years
  2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
  3. Written

Exclusion criteria

Exclusion Criteria:

  1. Tumors of the cerebellum, brainstem or midline
  2. Medical reasons precluding MRI (e.g. pacemaker)
  3. Inability to give written
  4. Secondary high-grade glioma due to malignant transformation from low-grade glioma
  5. Second primary within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
564 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tumor resection

    Tumor resection

    Procedure: Tumor resection

  • Tumor biopsy

    Tumor biopsy

    Procedure: Tumor biopsy

Interventions

  • ProcedureTumor resection

    Maximal safe resection of the tumor

  • ProcedureTumor biopsy

    Biopsy of the tumor

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time from diagnosis to death from any cause

    Time frame: Up to 5 years postoperatively

  2. Adjuvant treatment with chemotherapy and radiotherapy

    Proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy after surgery

    Time frame: 6 months postoperatively

Secondary outcomes

  1. Progression-free survival

    Time from diagnosis to disease progression (occurrence of a new tumor lesions with a volume greater than 0.175 cm3, or an increase in residual tumor volume of more than 25%) or death, whichever comes first

    Time frame: Up to 5 years postoperatively

  2. Neurological morbidity at 6 weeks

    NIHSS deterioration of 1 point or more at 6 weeks after surgery

    Time frame: 6 weeks postoperatively

  3. Neurological morbidity at 3 months

    NIHSS deterioration of 1 point or more at 3 months after surgery

    Time frame: 3 months postoperatively

  4. Neurological morbidity at 6 months

    NIHSS deterioration of 1 point or more at 6 months after surgery

    Time frame: 6 months postoperatively

  5. Quality of life at 6 weeks (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 weeks postoperatively

  6. Quality of life at 3 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 3 months postoperatively

  7. Quality of life at 6 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 months postoperatively

  8. Quality of life at 6 weeks (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 weeks postoperatively

  9. Quality of life at 3 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 3 months postoperatively

  10. Quality of life at 6 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 months postoperatively

  11. Quality of life at 6 weeks (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 weeks postoperatively

  12. Quality of life at 3 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 3 months postoperatively

  13. Quality of life at 6 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 months postoperatively

  14. Serious Adverse Events

    Serious Adverse Events within 6 weeks postoperatively

    Time frame: 6 weeks postoperatively

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2028, 60 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 60 months is close to that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2023
First posted
Nov 27, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06146725
Lead sponsor
Jasper Gerritsen
Responsible party
Jasper Gerritsen (Jasper K.W. Gerritsen MD PhD, Erasmus Medical Center) — Sponsor-investigator
First posted
Nov 27, 2023
Start date
Jan 1, 2023
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 27, 2023

Study contacts

Jasper Gerritsen, MD PhD
Contact
j.gerritsen@erasmusmc.nl
+31107036130
Arnaud Vincent, MD PhD
Contact
a.vincent@erasmusmc.nl
+31107034211
Jasper Gerritsen, MD PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion